NuVasive (NASDAQ: NUVA) today reported fourth-quarter results that missed the Wall Street consensus on earnings but beat on revenue.
The San Diego–based spine surgery tech company lost $36.7 million, or 71¢ per share, on sales of $302.1 million for the quarter ended Dec. 31, 2021 — versus a profit of $1.7 million, or 3¢ per share on sales of $291.8 million during Q4 2020.
Adjusted to exclude one-time items, earnings per share were 40¢, 8¢ behind The Street, where analysts were looking EPS of 48¢ on sales of $298.95 million.
“During 2021, we made significant progress on our strategy to deliver multiple vectors of growth, despite challenges with the COVID-19 pandemic,” CEO Chris Barry said in a news release out this evening.
“Our results reflect the organization’s continued evolution from the pioneer of lateral spine surgery to a company with leading procedural innovation across the spine continuum and increasing global scale. Through our focus on consistent execution and a commitment to increase shareholder value, our investments have built a technology pipeline which sets the stage for durable growth in 2022 — and for years to come.”
NuVasive expects 5–8% sales growth in 2022, with adjusted EPS in the $2.05–2.35 range. Wall Street analysts, on average, have predicted $2.31.
